Protein immobilization strategy to be applied to the SPR biosensing platform now commercialized by Nicoya Lifesciences.

虽然几十年来SPR生物传感器市场一直由Biacore仪器(GE Healthcare)主导， 几家初创公司最近推出了自己的负担得起的开放式SPR生物传感器。是这样的 位于滑铁卢的加拿大公司Nicoya Lifesciences就是这样的例子。现在的挑战之一是 该公司面临的问题是为他们的客户提供强大和通用的方案来捆绑蛋白质或 多肽在其生物传感器的表面以定向和稳定的方式存在，从而使表面具有多功能性 并且可重复使用。 巴黎理工大学和Nycoya生命科学公司之间的这个合作项目将包括开发 以及测试基于使用从头设计的多肽异二聚化系统的新方案 在Nicoya SPR生物传感器表面捕获嵌合蛋白。几个生物系统，例如 单抗或与其受体或与生长因子结合，将作为案例研究。 这是与德克雷森佐教授的实验室合作的项目，德克雷森佐教授是该领域的著名专家 战略规划将对实现这些目标具有战略意义。该项目将为Nicoya生命科学公司提供 多功能捕获工具将集成到他们的生物检测产品组合中。这些工具将很容易适应于 满足新客户的需求。这些活动还有可能显著改善 公司销售，因为他们将展示Nicoya仪器对单抗的适用性 量化市场。

While the SPR biosensor market has been dominated for decades by Biacore instruments (GE Healthcare), several startup companies have recently launched their own affordable open-architecture SPR biosensors. Such is the case for Nicoya Lifesciences, a Canadian company based in Waterloo (ON). One of the challenges now faced by the company is to provide their customers with robust and versatile protocols to tether proteins or peptides in an oriented and stable fashion at the surface of their biosensors, hence making the surface versatile and reusable. This collaborative project between École Polytechnique and Nycoya Lifesciences will consist in developing and testing novel protocols based on the use of a de novo designed peptide heterodimerizing system for the capture of chimeric proteins at the surface of Nicoya SPR biosensors. Several biological systems, e.g. monoclonal antibody or binding to their receptors or to growth factors, will serve as case studies. This Engage collaborative project with the laboratory of Prof. De Crescenzo, a renowned expert in the field of SPR, will be strategic to achieve these objectives. This project will provide Nicoya Lifesciences with a versatile capture tool to be integrated in their portfolio of bioassays. These tools will be readily adaptable to address the needs of their new customers. These activities also have the potential to drastically improve the company sales as they will demonstrate the applicability of Nicoya instruments to the monoclonal antibody quantitation market.